Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

The US Food and Drug Administration (FDA) has granted approval for a label update to Eli Lilly and Company's Amyvid ...

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

This week's dividend activity included increased payouts from General Mills (GIS) and Worthington Enterprises (WOR) as well ...

Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities ...

US pharma giant Eli Lilly has secured Indian regulatory approval to market Mounjaro, its widely used diabetes and weight-loss ...

Sascha Berger, private biopharmaceutical investor; Shannon Eaker, CTO of Xcellbio; Edwin Stone, CEO of Cellular Origins; and ...

Eli Lilly's Mounjaro diabetes and weight-loss drug approved in India in KwikPen device, offering personalized treatment ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...